Patients and oncologists are welcoming encouraging clinical trial news as the daraxonrasib trial gives pancreatic cancer hope against one of the deadliest and hardest-to-treat forms of cancer in the world. Updated findings from a clinical trial evaluating the targeted oral pill daraxonrasib alongside chemotherapy in 61 patients with newly diagnosed advanced pancreatic cancer that had spread to other organs were presented Friday in Barcelona at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Across an average follow-up of roughly 18 months, tumors shrank or disappeared in just over 60% of participants, cancer became undetectable on scans in roughly one in 12 patients (about 8%), and tumor growth was halted or controlled in roughly 90% of those treated.
Targeting KRAS Mutations and Improving One-Year Survival
Pancreatic cancer often goes undetected until it has already spread, leaving roughly half of diagnosed patients dead within three months and giving metastatic cases a dismal five-year survival rate of around 3%. Researchers say daraxonrasib stands out because it works as a KRAS inhibitor, targeting mutated RAS proteins that drive tumor growth in the vast majority of pancreatic cancers, mutations once widely considered “undruggable”.

About 76.6% of patients on the treatment were alive after one year, compared with historical averages of roughly 40% to 45% for standard chemotherapy alone. Tumours shrank or disappeared in about 60.7% of trial participants, with 8.2% showing no detectable disease on scans and roughly 90.2% achieving disease control over a median follow-up of 18.3 months. Because KRAS and related mutations also play a role in several other cancers, including certain lung and ovarian cancers, oncologists note the approach could eventually open doors to wider research.
Cautious Optimism Ahead of Larger Studies
Presenting the results, Dr. Wungki Park of Memorial Sloan Kettering Cancer Center in New York called the findings “the closest to cure” he had seen in metastatic pancreatic cancer, while Cancer Research UK chief executive Michelle Mitchell hailed the advance as the biggest leap forward in decades for the disease. Still, specialists emphasize that the study involved a relatively small group of 61 patients without a direct head-to-head comparison arm in that cohort, meaning larger and longer trials are needed to confirm long-term remission and regulatory approval pathways. Even so, as the daraxonrasib trial gives pancreatic cancer hope, families facing a grim diagnosis see a rare sign of real momentum against a relentless killer.
My View
Any genuine step forward against a disease as devastating as pancreatic cancer deserves celebration, especially for families who have spent decades hearing nothing but grim statistics.
At the same time, promising early trial results should never be turned into hype that misleads patients into thinking a cure is already sitting on pharmacy shelves tomorrow. Rigorous clinical trials exist for a reason: they test whether early shrinkage and survival gains hold up across larger populations and track side effects over time.
Equally important, once life-extending treatments do clear safety and effectiveness hurdles, healthcare systems must work to make them affordable and reachable rather than locking breakthroughs behind sky-high prices or slow bureaucracy. Hope is strongest when solid science is paired with honest expectations and fair access for every patient who needs it.




